The PennZone

  • Home
  • Non-profit
  • Technology
  • Education
  • Business
  • Construction
  • Entertainment
  • Health
  • Software

Dr. Jeff Gelblum Provides Alzheimer's Treatment to Patients in the US and Abroad
The PennZone/10277342

Trending...
  • New Home of the Month: Spacious Luxury Meets Modern Design in The Bristol at Heritage at Manalapan
  • Calvetta Phair, CEO America's Workforce Solution, LLC Assessed "Awardable" for Department of War work in the CDAO's Tradewinds Solutions Marketplace
  • Creative Investment Research Analysis Finds Slower GDP Growth, Rising Inflation
Alzheimer's Treatment
AVENTURA, Fla. - PennZone -- Dr. Jeff Gelblum, Neurologist at First Choice Neurology, has brought together clinical, imaging, and laboratory capabilities to provide rapid diagnosis and treatment to individuals suffering from Alzheimer's disease.

The patient journey of Alzheimer's evaluation and management involves a clinical assessment to determine the level of cognitive impairment, and imaging studies of the brain, MRI, and PET scans to identify the presence of brain amyloid plaques. Also included are laboratory capabilities to inform the tolerability of the new anti-Alzheimer medication, and an experienced infusion team capable of providing the new class of FDA-approved medication in a comfortable setting.

Dr. Gelblum's highly integrated program will eliminate the long delays and fragmented care that typically plague patients seeking Alzheimer's treatment.

He observes, "that the new class of disease-modifying treatments are only approved in mild Alzheimer's which offers only a short window of opportunity to treat. In the US and abroad, it can often take up to a year to get a neurology appointment, and by that point, the patient may have progressed to a point where they might no longer respond to treatment."

More on The PennZone
  • Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
  • $97.9 Million Q1 Revenue Growth Reinforces Transformation Into a Global AI & Digital Services Powerhouse: IQSTEL, Inc. (N A S D A Q: IQST)
  • Philadelphia Scientist Roohid Parast Applies Evidence-Based Research to Elite Personal Fitness
  • Boston Industrial Solutions Launches NatronĀ® 348 UV Inkjet Ink for Epson S3200 Print Heads
  • Heritage at South Brunswick Unveils Luxury Resort-Style Amenities Designed for Every Generation

Dr. Gelblum's program eliminates the delay and provides a quick and comprehensive work-up in the Aventura medical district, just north of Miami, Florida.

Dr. Gelblum boasts that "within 48 hours we can diagnose and begin infusion therapy.  This means that the patient can check in to our on-campus hotel on a Tuesday evening, undergo evaluation in our clinic Wednesday morning, receive diagnostic testing Wednesday and Thursday, and then obtain their infusion treatment on Friday."

For those patients who reside out of town, his infusion center can dispense medication to-go for follow-up infusion treatments in their hometown medical facility. This is ideal for out-of-town patients who may not have easy access to a neurologist. He can then follow the patient remotely via telehealth.

His Aventura clinic is easily accessible via Miami or Fort Lauderdale international airports.

Dr. Gelblum has a global patient population who has discovered the ease of access and convenience of care provided by this program. He has patients from the UK, Spain, France, Israel, Russia, South Korea, Central and South America, and the Caribbean. They are diagnosed in his Aventura clinic and then followed up remotely via Skype, WhatsApp, FaceTime, or any manner of live audiovisual interface.

More on The PennZone
  • CAPHRA warns push for ASEAN vape ban ignores science
  • Your Mortgage Toolbox Launches Free Mortgage Calculators That Show the Real Monthly Payment and Cash Needed to Close
  • ENTOUCH Recognized on Inc.'s 2026 Best Workplaces List for the Third Year Running
  • P-Wave Classics Opens Pre-Orders for Volume II of Robert Bage's Hermsprong
  • Cabinetworks Group announces recipient of 2025 Plant of the Year

Dr. Gelblum observes, "that in this day and age of disease-modifying therapy and instantaneous telecommunications, it is unacceptable for medically necessary neurological care and treatment to be delayed."

He looks forward to welcoming Alzheimer patients from all over to his Aventura, Florida clinic.

About Jeffrey Gelblum, MD, FAAN

Dr. Jeff Gelblum is a neurologist with First Choice Neurology located in Aventura, Florida. He is considered a global thought leader in the neurologic treatment of Alzheimer's, dementia, seizure disorders, Parkinson's, diabetic and peripheral nerve disorder, Familial Amyloid Polyneuropathy, Covid Long-Hauler, trauma, and chronic pain, and has hosted educational symposia in the U.S. and overseas. To learn more about Dr. Gelblum, visit https://www.fcneurology.net/business-directory/788/jeffrey-gelblum-md/

Contact
First Choice Neurology
***@fcneurology.net


Source: First Choice Neurology

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Blueshirt Media Launches HIPAA-Compliant AI Call Answering for Addiction Treatment Centers
  • AdvisorVault Adds Social Media Archiving to its Consolidated D3P Service
  • UK Financial Ltd Audits Full Ethereum Architecture Verifies Corporate Wallets and 19-Token Ecosystem Ahead of CoinMarketCap Filing for Global Ranking
  • Creative Investment Research Analysis Finds Slower GDP Growth, Rising Inflation
  • TechHouse Earns Highly Selective Microsoft Support Badge
  • J&J Exterminating Celebrates 65th Anniversary and Unveils Strategic Vision at Annual Team Meeting
  • Tru by Hilton El Paso Airport Opens to Guests
  • Zenylitics Announces Leadership Transition to Continue Accelerated Growth
  • Wellness Technology Distributor Helping People Set Up Wellness Center Businesses
  • Christian Apocalyptic Thriller Explores Biblical Prophecy, Global Technology, & the Rise of the Ant
  • Turnstone Creative Expands Leadership Team with Addition of Marketing Manager
  • The Hidden Price Of Lost Property In UK Schools
  • Milton Collier, CEO & President of Freight Broker 911, Eliminates the #1 Barrier to Entry in Logistics: Announces 100% Free Freight Broker Training
  • FDA-Cleared AI Neuropsychiatry Platform, Million-Dose Ketamine Manufacturing and Presidential Psychedelic Initiative Drive Growing Momentum for NRXP
  • AI Velocity Trading Launches Institutional-Grade Algorithmic Engine for Retail Investors
  • Calvetta Phair, CEO America's Workforce Solution, LLC Assessed "Awardable" for Department of War work in the CDAO's Tradewinds Solutions Marketplace
  • Speaker and Certified Coach Syrena N. Williams Debuts Powerful New Book on Healing, Identity, and Wholeness
  • Lord of the Rings, Doctor Who' Q&As, Local Sessions Highlight FAN EXPO Philadelphia Programming
  • Kryptokasinot.io Raises Concerns Over Proposed Cryptocurrency Restrictions in Finland's Gambling Reform
  • New Home of the Month: Spacious Luxury Meets Modern Design in The Bristol at Heritage at Manalapan

Popular on PennZone

  • People & Stories/Gente y Cuentos Welcomes Two New Trustees as Organization Enters 54th Year and Expands Community Reach
  • Resident Inspect Joins Property Meld Nexus Network with API Integration
  • Assymetrix Launches the Deepest Independent Prediction Market Data API
  • RAS AP Consulting Advances to RFP Stage in Heidelberg Materials' SAP Vendor & Customer Master Data Modernization Initiative
  • Expert E-Bike Safety Advocate Issues Urgent Warning Following Recent Southern California Fatalities
  • New Home of the Month: Spacious Luxury Meets Modern Design in The Bristol at Heritage at Manalapan
  • CCHR: 'Plant-Based' Psychedelics Push Masks Synthetic Drugs and Billion-Dollar Profits
  • "I'm Sicka Church Too: Give Me Kingdom!" Ignites a Powerful Call for Healing and Truth
  • Umbrella Becomes First FinOps Platform to Support AWS Billing Transfer Onboarding
  • Veikkaus Appoints New CFO as Finland's Gambling Monopoly Braces for Breakup

Similar on PennZone

  • Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
  • CAPHRA warns push for ASEAN vape ban ignores science
  • Lineus Medical Completes Financial Restructuring with KMF Investments- Launching a New Era for SafeBreak
  • Neuro Recovery Institute Showcases Emerging Immersive Neuro-Rehabilitation Technology at Clinical Innovation Open House
  • Industrial and systems engineers celebrate key leaders in the field at IISE Annual Conference
  • CCHR Leader's 50-Year Fight for Psychiatric Drug Victims Gains National Momentum
  • Author Releases 7-Day Screen Time Reset for Families as Teachers Worldwide Report Children "Struggling to Grasp Basic Concepts"
  • Men's Health Month Begins with Record Proclamations, AP News Coverage, & National Momentum for Men's Health
  • Blueshirt Media Launches HIPAA-Compliant AI Call Answering for Addiction Treatment Centers
  • TechHouse Earns Highly Selective Microsoft Support Badge
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us